The potential of ghrelin in cancer anorexia-cachexia

Jose M. Garcia, Aminah Jatoi, Egidio Del Fabbro

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The cancer anorexia-cachexia syndrome (CACS) is often seen in patients with incurable malignancies and is associated with increased mortality, decreased efficacy of anticancer treatments and poor quality of life. However, there are currently no effective therapies for CACS. Since CACS is a multifactorial syndrome with a complex pathophysiology, therapeutic interventions for CACS might potentially include anabolic agents as well as anti-inflammatory effects. Ghrelin affects numerous key pathways in the regulation of body weight and body composition through increased appetite and growth hormone (GH) secretion. Preliminary clinical data indicate that the administration of ghrelin and ghrelin receptor agonist such as anamorelin have beneficial effects on appetite and body weight in patients with CACS. Anamorelin is currently in phase III clinical trials.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalEuropean Oncology and Haematology
Issue number2
StatePublished - 2013


  • Anamorelin
  • Cancer anorexia-cachexia syndrome
  • Ghrelin

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'The potential of ghrelin in cancer anorexia-cachexia'. Together they form a unique fingerprint.

Cite this